• Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page

Layoffs 100%

Quote
















anonymous said:
There was still a portfolio to sell in 2016. Go to Market created a lot of new positions and weeded out most of the bottom feeders. This layoff will cut deep and not spare talent.
Click to expand...
A tremendous amount riding on the pipeline. We used to be a solid company with a strong portfolio and promising pipeline. Now, we are a 1 trick pony (Jardiance) and a gimpy mutt (OFEV). Established brands make a couple $$ but. It enough to offset the big miss on the budget. As far as ‘specialty’ products like Spevigo and Cyltezo? Well, those are not even a pimple on a gnat’s ass. The ‘success’ those had doesn’t bode well for future specialty products. BI should stick with CRM and Resp.
 




The new structure is visible in the BI share point files on Insite if you know where to look…..search project symphony. Go live is Jan 1st. Maybe they will speak to it on today’s town hall.
 












Top Bottom
Back
Quote